Lipocalin-2 (LCN2) has diverse functions in multiple pathophysiological conditions; however, its pathogenic role in vascular dementia (VaD) is unknown. Here, we investigated the role of LCN2 in VaD using rodent models of global cerebral ischemia and hypoperfusion with cognitive impairment and neuroinflammation. Mice subjected to transient bilateral common carotid artery occlusion (tBCCAo) for 50 min showed neuronal death and gliosis in the hippocampus at 7 days post-tBCCAo. LCN2 expression was observed predominantly in the hippocampal astrocytes, whereas its receptor was mainly detected in neurons, microglia, and astrocytes. Furthermore, Lcn2-deficient mice, compared with wild-type animals, showed significantly weaker CA1 neuronal loss, cognitive decline, white matter damage, blood-brain barrier permeability, glial activation, and proinflammatory cytokine production in the hippocampus after tBCCAo. Lcn2 deficiency also attenuated hippocampal neuronal death and cognitive decline at 30 days after unilateral common carotid artery occlusion (UCCAo). Furthermore, intracerebroventricular (i.c.v) injection of recombinant LCN2 protein elicited CA1-neuronal death and a cognitive deficit. Our studies using cultured glia and hippocampal neurons supported the decisive role of LCN2 in hippocampal neurotoxicity and microglial activation, and the role of the HIF-1α-LCN2-VEGFA axis of astrocytes in vascular injury. Additionally, plasma levels of LCN2 were significantly higher in patients with VaD than in the healthy control subjects. These results indicate that hippocampal damage and cognitive impairment are mediated by LCN2 secreted from reactive astrocytes in VaD.

No abstract

According to the World Health Organization in 2013, 235 million people are afflicted with asthma. Asthma is a severe pulmonary disease that can be caused by the imbalance of T-helper (Th) type 1 (Th1) and type 2 (Th2) cells, and it is potentially fatal. In this study, we evaluated the anti-asthmatic effect of alginate oligosaccharide (AO), which was prepared from seaweed and converted by Bacillus subtilis KCTC 11782BP, in the mouse model of ovalbumin (OVA)-induced asthma. BALB/c mice were divided into the vehicle control (sensitized but not challenged), asthma induction, positive control (1 mg/kg dexamethasone), 50 mg/kg/day AO-treated, 200 mg/kg/day AO-treated, and 400 mg/kg/day AO-treated groups. The numbers or levels of inflammatory cells, eosinophils, and immunoglobulin (Ig) E were measured in bronchoalveolar lavage fluid (BALF), and asthma-related morphological and cytokine changes were analyzed in lung tissues. Our results show that AO dramatically reduced inflammatory cell numbers, eosinophil count, and IgE levels in BALF, and it dose-dependently inhibited asthmatic histopathological changes in the lung. In addition, AO dose-dependently suppressed the expression of CD3+ T-cell co-receptors, CD4+ Th cells, CD8+ cytotoxic T-cell-related factors, macrophages, and MHCII class. AO dose-dependently decreased the expression levels of Th1/2 cells-regulatory transcription factors such as GATA-3 which modulates Th2 cell proliferation and T-bet which does Th1 cell proliferation. The mRNA levels of all Th1/2-related cytokines, except IL-12α, were dose-dependently suppressed by AO treatment. In particular, the mRNA levels of IL-5, IL-6, and IL-13 were significantly inhibited by AO treatment. Our findings suggest that AO has the potential to be an anti-asthmatic drug candidate, due to its modulation of Th1/Th2 cytokines, which contribute to the pathogenesis of asthma.

α-Synuclein (α-syn) is a major component of Lewy bodies found in synucleinopathies including Parkinson’s disease (PD) and Dementia with Lewy Bodies (DLB). Under the pathological conditions, α-syn tends to generate a diverse form of aggregates showing toxicity to neuronal cells and able to transmit across cells. However, mechanisms by which α-syn aggregates affect cytotoxicity in neurons have not been fully elucidated. Here we report that α-syn aggregates preferentially sequester specific synaptic proteins such as vesicle-associated membrane protein 2 (VAMP2) and synaptosomal-associated protein 25 (SNAP25) through direct binding which is resistant to SDS. The sequestration effect of α-syn aggregates was shown in a cell-free system, cultured primary neurons, and PD mouse model. Furthermore, we identified a specific blocking peptide derived from VAMP2 which partially inhibited the sequestration by α-syn aggregates and contributed to reduced neurotoxicity. These results provide a mechanism of neurotoxicity mediated by α-syn aggregates and suggest that the blocking peptide interfering with the pathological role of α-syn aggregates could be useful for designing a potential therapeutic drug for the treatment of PD.

have been developed for in vitro and in vivo bioimaging applications. CPDs have attracted considerable attention, because of their potential benefi ts such as relatively facile preparation, high fl uorescence (FL) emission quantum effi ciency, photostability, and low cytotoxicity. [ 2a ] However, CPDs still have some drawbacks, because of the characteristic electronic structures of conjugated polymers. First, in general, π-conjugated polymers have planar geometries and strong intermolecular interactions, because of the extremely stiff and rigid main chains, resulting in highly face-to-face chain packing in the solid state. [ 5 ] Although such an intermolecular π-stacked structure is essential for effective charge-carrier transport in the active layer in thin-fi lm organic optoelectronic devices, [ 6 ] the cofacial packing structure signifi cantly reduces the FL quantum effi ciency in bulk solid fi lms, because it produces crystal domains, and the formed intermolecular excimers have an extremely low transition energy in non-radiative processes. [ 7 ] CPDs are no exception to this rule. [ 2,8 ] Signifi cant FL attenuation has been observed in aqueous colloidal solutions compared with the usual organic solutions. Secondly, although CPDs have much higher photostabilities compared with other fl uorescent materials such as organic dyes [ 9 ] and green fl uorescent In this paper, specifi c molecular design rules are proposed for highly fl uorescent, photostable, conjugated polymer dots (CPDs) applicable for the bioimaging of live cells. CPDs are prepared by nanoprecipitation in water using polydiphenylacetylene (PDPA) derivatives and commercial conjugated polymers. Among these, an amorphous, glassy-state PDPA derivative provides highly porous, coarsened nanoparticles. The nanoparticles are dispersed very well in water, and the polymer chains are either hydrodynamically or thermodynamically stable, with a fully relaxed intramolecular stacked structure. This leads to effective radiative emission decays by restraining collisional quenching and vibrational relaxation to achieve an extremely high fl uorescence (FL) quantum effi ciency. The FL emission quantum yield is as high as 0.76, which is the highest value among those reported for conventional CPDs. The PDPA-based CPD has a very low photobleaching quantum yield (∼10 −9 ), because of its relatively high ionization potential. This aqueous colloidal solution is useful for bioimaging plant and mammalian cells. The excellent FL quantum effi ciency, photostability, and cellular uptake suggest that the present CPD is a very promising probe for bioimaging, particularly for long-term imaging and tracking in live cells or experimental animals.Recently, a wide range of fl uorescent nanoparticles such as inorganic semiconductor quantum dots, [ 1 ] conjugated polymer dots (CPDs), [ 2 ] conjugated polyelectrolyte dots, [ 3 ] and carbon dots [ 4 ]